Build status - In Progress

Study Of Avb-S6-500 In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Advanced Clear Cell Renal Cell Carcinoma Who Have Received Front-Line Treatment

Study Of Avb-S6-500 In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Advanced Clear Cell Renal Cell Carcinoma Who Have Received Front-Line Treatment
Recruiting
18 years - 99 years
All
Phase 2
25 participants needed
1 Location

Brief description of study

This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Clear Cell Renal Cell Carcinoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female 18 years of age or older Clear Cell Renal Cell Carcinoma

Updated on 04 Aug 2024. Study ID: 849104

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center